CellVoyant Technologies is a technology company.
CellVoyant Technologies has raised $10.0M across 1 funding round.
CellVoyant Technologies has raised $10.0M in total across 1 funding round.
CellVoyant Technologies has raised $10.0M in total across 1 funding round.
CellVoyant Technologies's investors include Business Growth Fund, Hummingbird Ventures, Octopus Ventures, Jonathan Milner.
CellVoyant Technologies is an AI-first biotechnology company focused on accelerating the development and manufacturing of novel stem cell-based therapies, particularly for chronic diseases. Their core product suite—FateView, FateCast, and FateSim—leverages live-cell imaging combined with advanced AI, including Bayesian Neural Networks, to non-destructively identify, predict, and control cell states and differentiation trajectories. This enables more efficient, scalable, and cost-effective cell and tissue manufacturing, primarily targeting induced Pluripotent Stem Cells (iPSCs) but with a platform generalizable to other cell types. CellVoyant serves biotech companies and researchers developing cell therapies, addressing challenges like destructive assays, long feedback loops, and variability in cell manufacturing[1][2][3].
Founded in Bristol, UK, CellVoyant emerged from foundational research at the University of Bristol, combining expertise in cell biology, computing, engineering, and machine learning. The company was founded by Rafael Carazo Salas and others with a vision to transform cell therapy development through AI-driven live-cell imaging. Early traction came from developing a closed-loop optimization platform that integrates label-free imaging and AI to autonomously steer cell manufacturing processes. Strategic investments from venture firms such as Octopus Ventures, Air Street Capital, and Horizons Ventures have supported its growth[1][2].
CellVoyant operates at the intersection of biotechnology, AI, and advanced imaging, riding the wave of increasing demand for scalable, reproducible cell and gene therapies. The timing is critical as the cell therapy market grows rapidly, with manufacturing bottlenecks and quality control challenges limiting broader adoption. Their technology addresses these market forces by enabling real-time, non-destructive monitoring and control, reducing costs and accelerating development timelines. This positions CellVoyant as a key enabler in the evolving ecosystem of regenerative medicine and personalized therapies, influencing how cell therapies are developed and manufactured globally[1][2][4].
Looking ahead, CellVoyant is poised to expand its platform capabilities and industry partnerships, potentially broadening its impact beyond iPSCs to other cell types and therapeutic areas. Trends such as AI integration in bioprocessing, demand for automation, and personalized medicine will shape its trajectory. As regulatory frameworks evolve to accommodate AI-driven manufacturing, CellVoyant’s technology could become a standard for quality assurance and process optimization in cell therapy production. Their continued innovation and scaling could significantly influence the efficiency and accessibility of advanced cell therapies worldwide[1][2][4].
CellVoyant Technologies has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Seed in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $10.0M Seed | Business Growth Fund, Hummingbird Ventures, Octopus Ventures, Jonathan Milner |